MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. by Hegi, M.E. et al.
   
 
 
 
 
Serveur Acade´mique Lausannois SERVAL serval.unil.ch
Author Manuscript
Faculty of Biology and Medicine Publication
This paper has been peer-reviewed but does not include the final publisher
proof-corrections or journal pagination.
Published in final edited form as:
Title: lt;igt;MGMTlt;/igt; Promoter Methylation Cutoff with Safety
Margin for Selecting Glioblastoma Patients into Trials Omitting
Temozolomide: A Pooled Analysis of Four Clinical Trials.
Authors: Hegi ME, Genbrugge E, Gorlia T, Stupp R, Gilbert MR, Chinot
OL, Nabors LB, Jones G, Van Criekinge W, Straub J, Weller M
Journal: Clinical cancer research : an official journal of the American
Association for Cancer Research
Year: 2019 Mar 15
Issue: 25
Volume: 6
Pages: 1809-1816
DOI: 10.1158/1078-0432.CCR-18-3181
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.
Hegi et al 
1 
 
MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma 
Patients into Trials Omitting Temozolomide. A Pooled Analysis of Four Clinical Trials. 
 
Monika E. Hegi1, Els Genbrugge2, Thierry Gorlia2, Roger Stupp3, Mark R. Gilbert4, Olivier 
Chinot5, L. Burt Nabors6, Greg Jones7, Wim Van Criekinge8, Josef Straub9, Michael Weller10 
 
Affiliations: 
1Neurosurgery & Neuroscience Research Center, Lausanne University Hospital, Lausanne, 
Switzerland; 
2 European Organisation for Treatment and Research of Cancer (EORTC) Data Centre, 
Brussels, Belgium;  
3Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Northwestern 
University Feinberg School of Medicine, Chicago, IL; 
4National Cancer Institute, National Institutes of Health, Bethesda, MD; 
5Aix-Marseille University, AP-HM, Hôpital de la Timone, Marseille, France;  
6University of Alabama at Birmingham, Birmingham, AL;  
7MDxHealth, Irvine, CA; current Inivata, Research Triangle Park, NC; 
8Department of Mathematical Modeling, Statistics and Bio-Informatics, Ghent University, 
Ghent, Belgium; 
9Merck KGaA, Darmstadt, Germany; 
10Department of Neurology, University Hospital Zurich, Zurich Switzerland. 
 
Running Titel: MGMT Safety Margin for Glioblastoma 
 
Corresponding author: 
Monika E Hegi, Lausanne University Hospital, chemin des Boveresses 155, CLE-C306, 
1066 Epalinges, Switzerland;  
Email: monika.hegi@chuv.ch 
Hegi et al 
2 
 
Disclosure of Potential Conflicts of Interest: 
M.E.H. reports research grants from Orion, and her institution receives free MGMT testing 
from MDxHealth. 
E.G. reports no competing interests 
T.G. reports no competing interests  
R.S. received non-financial support from Novocure; his institution received honoraria from 
Roche, Merck KGaA, MSD, Merck, and Novartis.  
M.R.G. reports no competing interests. 
O.C. reports grants, personal fees and non-financial support from Roche, and personal fees 
from Ipsen, AstraZeneca, Celdex and Abbvie. 
L.B.N reports no competing interests 
G.J. is a current employee of Inivata and a consultant of MDxHealth  
W.V.C. is a consultant of MDxHealth. 
J.S. is an employee of Merck KGaA; this study does not reflect an official view of KGaA. 
M.W has received research grants from Abbvie, Acceleron, Actelion, Bayer, Merck, Sharp & 
Dohme (MSD), Merck (EMD), Novocure, OGD2, Piqur, Roche and Tragara, and honoraria 
for lectures or advisory board participation or consulting from Abbvie, BMS, Celgene, 
Celldex, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, Orbus, Pfizer, Progenics, 
Roche, Teva and Tocagen. 
 
  
Hegi et al 
3 
 
Translational Relevance 
MGMT-testing is disputed, which hinders stratified therapy and clinical trials omitting 
temozolomide. It is therefore of importance to determine the clinically relevant cutoff(s) 
defining the MGMT promoter methylation status for glioblastoma that allows safe clinical 
decision making and patient selection into trials omitting temozolomide. 
The pooled analysis of quantitative MGMT MSP (methylation-specific PCR) data from 4041 
glioblastoma patients screened or randomized in four clinical trials allowed determination 
and validation of an unsupervised cutoff and a lower cutoff supervised by outcome. The 
latter defines a “grey zone” comprising patients with low MGMT methylation who performed 
significantly better than truly unmethylated patients. This lower safety margin is suitable for 
selecting truly unmethylated patients for stratified therapy to spare patients unnecessary 
toxicity.  
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Abstract 
Purpose: The methylation status of the O6-methylguanine DNA methyltransferase (MGMT) 
gene promoter is predictive for benefit from temozolomide in glioblastoma. A clinically 
optimized cutoff was sought allowing patient selection for therapy without temozolomide, 
while avoiding to withhold it from patients who may potentially benefit. 
Experimental Design: Quantitative MGMT methylation-specific PCR data were obtained for 
newly diagnosed glioblastoma patients screened or treated with standard radiotherapy and 
temozolomide in four randomized trials. The pooled dataset was randomly split into a 
training and test dataset. The unsupervised cutoff was obtained at a 50% probability to be 
(un)methylated. Receiver operating characteristics (ROC) analysis identified an optimal 
cutoff supervised by overall survival (OS).  
Results: For 4041 patients valid MGMT results were obtained, whereof 1725 were 
randomized. The unsupervised cutoff in the training dataset was 1.27 
(log2[1000x(MGMT+1)/ACTB]), separating unmethylated and methylated patients. The 
optimal supervised cutoff for unmethylated patients was -0.28 (AUC=0.61), classifying “truly 
unmethylated” (≤-0.28) and “grey zone” patients (>-0.28, ≤1.27), the latter comprising ~10% 
of cases. In contrast, for MGMT methylated patients (>1.27) more methylation was not 
related to better outcome. Both methylated and grey zone patients performed significantly 
better for OS than truly unmethylated patients (HR=0.35, 95% CI: 0.27-0.45, p<0.0001; 
HR=0.58, 95% CI: 0.43-0.78, p<0.001), validated in the test dataset. The MGMT assay was 
highly reproducible upon retesting of 218 paired samples (R2=0.94).  
Conclusions: Low MGMT methylation (grey zone) may confer some sensitivity to 
temozolomide treatment, hence the lower safety margin should be considered for selecting 
unmethylated glioblastoma patients into trials omitting temozolomide. 
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Introduction 
A predictive role has been shown for the methylation status of the O6-methylguanine DNA 
methyltransferase (MGMT) gene promoter for benefit from Temozolomide (TMZ) in newly 
diagnosed glioblastoma patients (1-4). Consequently, the MGMT methylation status is used 
as a stratification factor in trials comprising TMZ treatment. All contemporary trials have 
confirmed the strong prognostic role of the MGMT status in glioblastoma patients treated 
with the combination of radiation concurrent with TMZ, followed by maintenance TMZ 
(TMZ/RTTMZ) (1, 5-10).The lack of efficacy of TMZ in MGMT unmethylated glioblastoma 
warrants replacement with an agent with a different mechanisms of action, or omission of 
TMZ to avoid futile therapy and associated toxicity. Trials specifically designed to selecting 
only MGMT unmethylated glioblastoma patients and replacing TMZ in the experimental arm 
are becoming a common strategy in clinical research (11-14) (CheckMate 498, 
NCT02617589; N2M2, NCT03158389). However, the best way of assessing the MGMT 
promoter methylation status remains strongly debated (15). It remains unclear which pattern 
and extent of MGMT promoter methylation is required to prevent MGMT mediated DNA 
repair that sensitizes glioblastoma patients to alkylating agent chemotherapy. A correlation 
of the extent of MGMT promoter methylation with outcome in patients treated with TMZ 
chemo-radiotherapy has been suggested (16, 17). Accurate and reproducible assays with 
clinically relevant cutoffs are required, in order not to withhold TMZ from patients who may 
potentially benefit, while sparing others from unnecessary toxicity and cost.  
 
In the present analysis we aim at revisiting the MGMT methylation cutoff using the pooled 
datasets of recent prospective randomized clinical trials, which had used the same 
quantitative, methylation specific PCR (qMSP) MGMT assay (18, 19) and had delivered the 
identical backbone treatment of TMZ/RTTMZ to newly diagnosed glioblastoma patients. 
These combined datasets provide the unique opportunity to explore and validate the 
relationship between the extent of MGMT promoter methylation and overall survival (OS). 
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The specific goals of this research project are (i) re-evaluation of the technical 
(unsupervised) cutoff that discriminates methylated and unmethylated patients, whereby 
patients have a 50% probability to be methylated or unmethylated, (ii) definition of an optimal 
cutoff for glioblastoma patients, supervised by overall survival (OS), (iii) validation of the 
findings in an independent test dataset, (iv) evaluation of the assay reproducibility, and 
finally (v) comparison to the current assay-based classification used in routine diagnostics. 
The overarching goal is to provide one or more cutoffs that allow treatment decisions for 
personalized therapy and appropriate selection of patients into clinical trials omitting TMZ. 
 
Patients and methods   
Data Selection 
Quantitative MGMT promoter methylation data was obtained from four trials for newly 
diagnosed glioblastoma, with central MGMT testing by the same qMSP assay, applying the 
same cutoff [1 in log2 space; log2 (
𝑀𝐺𝑀𝑇
𝐴𝐶𝑇𝐵
 × 1000)] (18, 19), and using the standard 
TMZ/RTTMZ schedule as backbone treatment (5). Patients with available MGMT 
classification (n=4458) had been randomized into (i) the control arm of the phase III AVAGlio 
trial (n=472, NCT00943826) (8), (ii) the control or experimental arm of the RTOG 0825 
phase III trial (n = 621, NCT00884741) (7), (iii) the control or experimental arm of the 
CENTRIC (phase III) or CORE (phase II) trials that selected patients with a methylated or 
unmethylated MGMT promoter, respectively (n = 545, CENTRIC NCT00689221; n = 265, 
CORE NCT00813943) (18, 20); or (iv) patients who were screened, but neither randomized 
in CENTRIC (n = 2328) nor CORE (n = 227) (n=3365). All four selected trials failed to 
demonstrate improvement in overall survival of the experimental arm based on hazard ratios 
as reported. For randomized patients survival data and baseline information with respect to 
age, extent of surgery, and performance status were available. Data can be applied for via 
the following weblink: http://www.eortc.be/services/forms/erp/request.aspx. 
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Constitution of Training and Test Cohort 
For the present analysis, only samples passing the quality threshold for providing a “valid” 
test result (≥1250 copies of the normalizer gene β-actin, ACTB) were considered. This all 
patients (all-P) population included both randomized and screened patients, whereas the 
randomized patients (rand-P) population was a subset of the all-P population. The data was 
randomly split into a training and a test cohort, stratified for trial, extent of resection 
(complete resection, partial resection, biopsy only, other), and performance status (PS=0, 
PS≥1). The all-P training cohort was used for the unsupervised analyses, while the rand-P 
training cohort was used for the supervised analyses of the relationship between the extent 
of MGMT methylation and OS. Validation of the findings was performed in the all-P and 
rand-P test cohorts, respectively.  
 
Retest Dataset 
A cohort of patients was selected randomly among patients screened but not randomized for 
CENTRIC. Retest tissue sections had been set aside for this purpose as of protocol, if 
enough tissue was available. Sample identifiers of retest tissue sections were blinded 
(relabeled). The initial MGMT testing was performed at the certified MDxHealth site in Liège, 
Belgium and retesting took place at their laboratory in Irvine, CA, USA. Only samples with 
valid ACTB results in both the original and retest data were selected.  
 
All protocols were approved by the local ethics committees or institutional review boards and 
competent authorities, and patients provided written informed consent for trial participation 
and/or participation in marker screening including retesting. The trials were performed 
according to the guidelines of Helsinki (21). 
 
Quantitative Methylation-Specific PCR MGMT Assay 
The qMSP MGMT test was performed and evaluated essentially as described (18, 19) and is 
commercially available (PredictMDx test). In brief, DNA was isolated from sections of macro-
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dissected FFPE tumor tissue. After bisulfite treatment the copy numbers of methylated 
MGMT and the reference gene ACTB were determined by quantitative PCR. A valid test 
required a minimum of 1250 ACTB copies measured. 
For this study the calculation of the ratio of the MGMT and ACTB copy numbers was slightly 
modified as compared to the original procedure (19) by adding one MGMT copy to the 
numerator: log2 (
𝑀𝐺𝑀𝑇+1
𝐴𝐶𝑇𝐵
 × 1000). The result is termed corrected MGMT log2 ratio hereafter. 
Samples with zero MGMT copies would otherwise be lost after logarithmic transformation. 
For the calculations the original MGMT values were used, ignoring the technical limit of 
detection of the assay set at ≥ 10 copies of methylated MGMT. 
 
Determination of the Unsupervised Cutoff and MGMT Methylation Status  
We applied a bimodal Gaussian mixture distribution to model the corrected MGMT log2 ratio. 
The unsupervised cutoff in the all-P training cohort, defined as the 50% probability to be 
(un)methylated, was used to classify patients as unmethylated (≤ cutoff point) or methylated 
(> cutoff point). The same cutoff was used to classify the patients in the test cohort. 
 
Determination of the Optimal Cutoff Supervised by OS 
To identify an optimal cutoff point supervised by OS in both unmethylated and methylated 
patients in the rand-P training cohort, time-dependent Receiver Operating Characteristic 
(ROC) analysis with nearest neighbor estimation was used (22). OS predictions at two years 
were made in both groups. The optimal supervised cutoff point was chosen as the value that 
maximized the Youden’s index, if the area under the curve (AUC) was >0.6, otherwise no 
cutoff point was determined. The optimal supervised cutoff point was used to classify 
patients further, both in the training and test populations.  
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Statistical Analysis 
The all-P and rand-P training and test cohorts were compared using descriptive statistics. 
Categorical variables are presented as frequencies and percentages. Continuous variables 
are described by their median and interquartile range (IQR). Initial comparison of OS by 
MGMT status was performed using Kaplan Meier (KM) plots accompanied by a log-rank test.  
A univariate Cox model assessed the effect of MGMT methylation status on OS, whereas a 
multivariate Cox model was used for sensitivity purposes. All survival analyses were 
stratified by trial. Statistical significance was determined at the 2-sided 5% significance level.  
 
Assay MGMT methylation status reproducibility and comparison with the original procedure 
was quantified using Cohen’s Kappa coefficient. The original procedure uses the 
uncorrected MGMT log2 ratio with a cutoff of 1 and a lower safety margin of -0.75. This cutoff 
was based on 602 patient samples from CENTRIC, and the lower safety margin was set at 
the lower bound 95% CI of being unmethylated as described (12). A limit of detection of the 
diagnostic assay was also applied that sets <10 methylated MGMT copies to unmethylated. 
 
All analyses were carried out in R version 3.3.0. 
 
Results 
Descriptive Analyses 
Valid qMSP MGMT results were available for 4041 patient samples (all-P population; 90.6% 
of all available samples), consisting of 2316 patients screened only (57.3%) and 1725 
randomized patients (rand-P population, 42.7%) (Fig. 1). Only for the latter full treatment and 
survival outcome data were available. The All-P population was randomly split into a training 
and test cohort stratified for trial and clinical factors, respectively comprising 2021 and 2020 
patients. The rand-P training and test cohorts contained 863 and 862 patients, respectively. 
Hegi et al 
10 
 
The origin of the patients (trial) and baseline characteristics are summarized in Table 1 and 
were balanced between cohorts.  
 
Assay Reproducibility  
The reproducibility of the assay was evaluated in 218 paired sample sets with ACTB copies 
≥ 1250 in both the original and retest data. Retest values for the corrected MGMT log2 ratio 
were plotted in function of the original values (Fig. 2). The coefficient of determination (R2) 
was >93%, indicating that most of the variability in the retest data could be explained by the 
original data. 
 
Unsupervised Technical Cutoff  
The unsupervised cutoff for the corrected MGMT log2 ratio, separating methylated and 
unmethylated samples, was equal to 1.27 on the log2 scale (Fig. 3A). After assignment of the 
MGMT methylation status there were 1332 unmethylated patients (65.9%) and 689 
methylated patients (34.1%) in the all-P training cohort.  
 
Association between MGMT Methylation Status and OS  
The median OS from randomization in the whole rand-P training cohort was 19.3 months 
(95% CI, 17.5–20.7). Baseline characteristics were balanced between the 460 MGMT 
unmethylated patients (53.3%) and 403 methylated patients (46.6%) (supplementary Table 
S1). Median OS was 14.5 months (95% CI, 14.0-15.3) and 26.5 months (95% CI, 25.1-30.2), 
respectively (Fig. 3B). MGMT methylated patients had a significantly longer OS compared to 
unmethylated patients (log-rank test, p<0.0001; HR=0.39, 95% CI, 0.30-0.50). Similar results 
were obtained in the multivariate analysis (supplementary Table S2). 
 
Supervised Optimal Cutoff 
For the unmethylated patients in the rand-P training cohort a time-dependent ROC curve 
with an AUC equal to 0.61 was obtained, resulting in an optimal cutoff point of -0.28 on the 
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log2 scale (Supplement Fig. S1A). This corresponds to a 96% probability of being 
unmethylated as visualized in Figs 4A and 4B. In contrast, for the methylated patients the 
ROC curve yielded an AUC of 0.50, suggesting no association between extent of 
methylation and outcome (supplementary Fig. S1B). 
 
Lower Safety Margin and OS  
The optimal supervised cutoff of -0.28 obtained in the unmethylated rand-P training subset 
was applied as a lower safety margin in the entire rand-P training cohort. The grey zone 
comprised 82 patients (9.5%), while 378 patients (43.8%) were labeled as truly 
unmethylated. The KM plot is displayed in Fig. 4C and the survival curves differed 
significantly according to the log rank test (p<0.0001). Univariate Cox regression analysis 
resulted in a HR of 0.35 (95% CI: 0.27- 0.45, p<0.0001) for the methylated patients, and a 
HR of 0.58 for patients in the grey zone (95% CI, 0.43-0.78, p<0.001), respectively, when 
compared to the truly unmethylated patients. Similar results were obtained in the multivariate 
analysis (Table 2). 
 
Validation of Unsupervised Cutoff and Supervised Safety Margin and OS in the 
Independent Test Cohort 
There were 375 truly unmethylated patients (43.5%), 70 grey zone patients (8.1%), and 417 
methylated patients (48.4%) in the rand-P test cohort. The median OS in the whole rand-P 
test cohort was 17.7 months (95% CI, 16.7-19.3). MGMT methylated patients had a 
significantly longer OS compared to unmethylated patients (supplementary Table S2, 
supplementary Fig. S2A). When including the lower safety margin, the survival curves 
differed significantly (log rank test, p<0.0001, Fig. S2B in the Supplement). The univariate 
Cox model resulted in a HR of 0.38 (95% CI, 0.29-0.49, p<0.0001) for the methylated 
patients, and a HR of 0.70 for patients in the grey zone (95% CI, 0.51- 0.96, p=0.03), both 
compared to the truly unmethylated patients. Similar results were obtained in the multivariate 
model (Table 2).  
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Good classification in retest dataset 
Application of the 1.27 unsupervised cutoff to the retest dataset of 218 paired samples 
yielded 8 methylation status mismatches (3.7%; supplementary Table S3). Cohen’s Kappa 
coefficient for inter-rater agreement was 0.93 (95% CI, 0.88-0.98) indicating almost perfect 
agreement between the original and retest methylation status. After also applying the lower 
safety margin the Kappa value was 0.80 (95% CI, 0.73-0.88), still indicating almost perfect 
agreement (supplementary Table S4). A Kappa-value of 0.89 (95% CI, 0.83- 0.95) was 
obtained, when in addition applying the limit of detection of the diagnostic qMSP assay that 
considers <10 copies of methylated MGMT below the limit of detection and classifies them 
as unmethylated by default (supplementary Table S5).  
 
Comparison of the validated new classification with the original procedure  
When comparing our classification method to the original procedure and cutoff (18, 19) in 
both the all-P training and test cohort, Cohen’s Kappa coefficients of respectively 0.93 (95% 
CI: 0.92 – 0.94) and 0.95 (95% CI, 0.94-0.96) were obtained, indicating almost perfect 
agreement (supplementary Table S6). When the limit of detection of the diagnostic assay 
was applied, the comparison between the original and new classification method 
(supplementary Table S7) resulted in a Cohen’s Kappa value of 0.98 (95% CI, 0.97-0.99) in 
the both the all-P training and test cohorts.  
 
Discussion 
We aimed at determining a clinically relevant cutoff for the qMSP MGMT assay that is most 
widely used in clinical trials for patient stratification and, more importantly, for treatment 
strategies omitting TMZ in patients with unmethylated glioblastoma. The technical cutoff of 
the MGMT assay used has been defined as the value where the probability of being 
methylated or unmethylated is 50% (18, 19). The uncertainty regarding the methylation 
status close to the cutoff is high. Our pooled analysis from four randomized trials allowed 
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determination and validation of the technical cutoff as well as a clinically relevant cutoff, 
supervised by OS in a large pooled dataset of patients treated uniformly with the current 
standard of care (TMZ/RT  TMZ).  
 
This supervised optimal cutoff (-0.28, corrected MGMT log2 ratio) was situated below the 
technical cutoff obtained (1.27) and represents a lower safety margin which defines a grey 
zone of “low” methylation (Fig. 2). Patients whose MGMT value was situated in this grey 
zone did significantly better than those classified as “truly” MGMT unmethylated (<-0.28). 
Application of the lower safety margin in trials comparing schedules of TMZ/RT  TMZ to 
RT only (4) may shed new light on the interpretation of the apparent “low benefit” from TMZ 
in the “MGMT unmethylated” population. Consequently, grey zone patients may benefit from 
TMZ treatment and should not be considered for treatments withholding TMZ.  
 
In contrast, among patients classified as MGMT methylated (>1.27, above the technical 
cutoff), a higher extent of methylation was not associated with a further gain in OS. This may 
suggest that detection of MGMT methylation in GBM using this assay is indicative of the 
second hit, completely inactivating MGMT. The first hit is the GBM characteristic loss of one 
copy of chromosome 10 on which MGMT resides (10q26) (23). For tumor types retaining 
both copies of MGMT other clinical cutoffs may apply predicting sensitivity to TMZ/alkylating 
agents as we have recently reported for IDH mutated grade II glioma treated with TMZ or RT 
in the EORTC-22033 randomized phase III trial (24, 25). 
 
Comparison of the here presented OS-supervised MGMT classification (methylated, grey 
zone or unmethylated) with the original classification and cutoffs (12, 18) revealed a high 
level of agreement. In the original classification procedure we had defined the safety margin 
as the 95% probability to be unmethylated (12) based on theoretical considerations as it is 
unknown which methylation pattern and how much methylation is required for complete 
silencing of MGMT expression in glioblastoma (26). This safety margin was applied for 
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patient selection into trials omitting TMZ (12, 13). This boundary is very similar to the safety 
margin determined with the OS supervised analysis in this study that corresponds to a 96% 
chance of being unmethylated. Thus, our study now demonstrates the clinical importance of 
respecting a grey zone by providing the respective supporting outcome data. Implementation 
of the safety margin essentially groups methylated and grey zone results into the TMZ 
requiring patient population and selects the truly unmethylated patients as suitable for 
treatment without TMZ. This needs to be taken into account for clinical trial planning. 
 
Despite the large dataset and high reproducibility of the assay (R2=0.94) our study suffers 
from some limitations. All analyses were retrospective, which might have caused patient 
selection and cannot guarantee that training and test cohorts were balanced in terms of 
unmeasured confounders. In addition, no survival data was available for screened patients 
only, reducing the sample size for supervised and subgroup analyses. Yet, no better 
datasets to address this important issue for clinical practice and future clinical trial design is 
likely to become available. 
 
It is important to note that the extent of methylation as measured and quantified by different 
MGMT tests may not necessarily have the same biological significance. Distinct tests use 
different principles (15) and/or interrogate different CpGs that do not all have the same 
impact on MGMT silencing (26-28), which is the principle mechanism for sensitizing patients 
to TMZ. Consequently, cutoffs and corresponding safety margins need to be determined and 
validated for each assay (17, 29-31).  
 
In conclusion, the present analysis demonstrates that the qMSP assay is robust and 
technically reproducible, and confirms the strong impact of MGMT methylation on outcome 
in a large clinical trial populations treated with TMZ/RTTMZ. The re-establishment of the 
cutoffs in a large dataset with a slightly different calculation model and using outcome 
information, yielded almost identical classification into methylated, grey zone, and truly 
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unmethylated patients as compared to the original procedure described (12). The clinically 
relevant cutoff informed by OS defined a grey zone with a safety margin that identifies 
patients who perform significantly better than truly unmethylated patients and may have 
some benefit from TMZ. This grey zone could be validated in an independent dataset 
indicating that these patients should not be selected for treatment schemes avoiding TMZ.  
 
With this study we aim to encourage stratified TMZ treatment for glioblastoma patients 
implementing a safety margin for guiding treatment decisions. This should facilitate testing 
new treatment paradigms without TMZ in MGMT unmethylated GBM patients who direly 
need better treatments.  
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Figure Legends 
Figure 1. Flow of patient samples through the study. all-P, all patients population; rand-
P, randomized patient population; ACTB, -actin gene. 
 
Figure 2. Reproducibility of qMSP MGMT assay. 
The Original and Retest dataset (corrected MGMT log2 ratios, [log2 (
𝑀𝐺𝑀𝑇+𝟏
𝐴𝐶𝑇𝐵
× 1000)]) from 
218 paired samples are visualized in a scatter plot. The R-squared was 93%. Retests were 
performed using a second set of FFPE tumor sections in a different laboratory blinded to the 
original results. 
 
Figure 3. Unsupervised MGMT promoter methylation cutoff and OS.  
The unsupervised cutoff of 1.27 obtained in the all-P training cohort is indicated in green in 
the bimodal distribution of the corrected MGMT log2 ratio values [log2 (
𝑀𝐺𝑀𝑇+𝟏
𝐴𝐶𝑇𝐵
× 1000)] (A). 
The Kaplan Meyer plot visualizes OS in the rand-P training cohort separated into patients 
with MGMT promoter-methylated and -unmethylated tumors (p<0.0001, logrank test). The 
shaded area represents the 95% confidence interval. 
 
Figure 4. Optimal MGMT promoter methylation cutoff and OS. 
The position of the optimal cutoff point of -0.28 [corrected MGMT log2 ratio value, log2 
(
𝑀𝐺𝑀𝑇+𝟏
𝐴𝐶𝑇𝐵
× 1000)] is indicated in orange in the bimodal distribution of the entire all patients 
(all-P) training cohort (A). It corresponds to a 96% chance to be unmethylated (4% chance to 
be methylated) as illustrated in the posterior probability plot (B) and defines the lower bound 
of the “grey zone“ (-0.28, and ≤1.27). The Kaplan Meyer plot visualizes (C) the outcome of 
patients in the randomized patient (rand-P) training cohort separated into MGMT promoter 
methylated (<1.27), grey zone (-0.28, and ≤1.27), and truly unmethylated patients (<-0.28) 
(p<0.0001, logrank test). The shaded area represents the 95% confidence interval. 
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Table 1. Patient origin (trial) and baseline characteristics of split datasets  
 
a all-P, all patients population; b rand-P, randomized patients population 
  
 TRAINING cohort (%) 
 
TEST cohort (%) 
 
 all-P 
a (n=2021) rand-P b (n=863) all-P a (n=2020) rand- P b (n=862) 
Trial 
CENTRIC (randomized) 264 (13.1) 264 (30.6) 262 (13.0) 262 (30.4) 
CENTRIC (screened) 1058 (52.4) NA 1058 (52.4) NA 
CORE (randomized) 132 (6.5) 132 (15.3) 133 (6.6) 133 (15.4) 
CORE (screened) 100 (4.9) NA 100 (5.0) NA 
AVAGlio 170 (8.4) 170 (19.7) 170 (8.4) 170 (19.7) 
RTOG 0825 297 (14.7) 297 (34.4) 297 (14.7) 297 (34.5) 
Baseline Characteristics  
Performance status (randomized patients only) 
PS = 0 NA 516 (59.8) NA 514 (59.6) 
PS ≥ 1 NA 347 (40.2) NA 345 (40.0) 
Missing NA 0 (0) NA 3 (0.4) 
Extent of resection (randomized patients only)  
Complete resection NA 454 (52.6) NA 453 (52.6) 
Partial resection NA 394 (45.7) NA 392 (45.5) 
Biopsy only NA 6 (0.7) NA 7 (0.8) 
Other NA 8 (0.9) NA 8 (0.9) 
Missing NA 1 (0.1) NA 2 (0.2) 
Age in years (randomized patients only) 
Median (Q1,Q3) NA 57 (50, 63) NA 57.5 (50, 64) 
Corrected log2 MGMT ratio 
Median (Q1,Q3) -0.58 (-2.00, 3.24) 0.63 (-1.97, 4.77) -0.58 (-1.96, 3.54). 1.06  (-1.79, 4.94) 
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Table 2. Outcome by MGMT promoter methylation status in the rand-P training & test cohorts. 
Methylation status N (%) Observed 
Events 
Median survival 
[months] 
HR (95% CI) P-value  Adj. HR (95% CI)a Adj. P-value  
Training cohort        
Truly unmethylated 378 (43.8) 302 14.0 (13.1 – 14.7) 1.00   1.00   
Grey zone  82 (9.5) 50 18.5 (16.2 – 25.0) 0.58 (0.43 – 0.78) <0.001 0.64 (0.47 – 0.87) <0.01 
Methylated  403 (46.7) 203 26.5 (25.1 – 30.2) 0.35 (0.27 – 0.45) <0.0001 0.32 (0.25 – 0.42) <0.0001 
Test cohort        
Truly unmethylated 375 (43.5) 299 13.6 (12.9 – 14.7) 1.00   1.00   
Grey zone  70 (8.1) 46 16.5 (13.8 – 20.6) 0.70 (0.51 – 0.96) 0.03 0.71 (0.52 – 0.97) 0.03 
Methylated  417 (48.4) 219 25.6 (23.2 – 28.4) 0.38 (0.29 – 0.49) < 0.0001 0.36 (0.28 – 0.46) < 0.0001 
a adjusted for age, ECOG performance status, and extent of resection 
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